002172.SZ(002172.SZ)
002172.SZ
Jiangsu Aoyang Health Industry Co., Ltd. is a Chinese chemical manufacturer specializing in the production of pharmaceutical intermediates and fine chemicals. The company operates primarily in Jiangsu province, leveraging its advanced production capabilities and R&D to maintain a competitive edge in the domestic market.
The company generates revenue through the sale of chemical products, primarily to pharmaceutical companies. Its competitive advantages include a strong R&D focus that allows for innovation in product offerings and a well-established distribution network within China.
Fluctuations in raw material prices, particularly for key inputs like benzene and toluene
Changes in regulatory policies affecting the chemical industry in China
Demand shifts in the pharmaceutical sector, particularly for generic drugs
Capacity expansion or new product launches
Regulatory changes that could impose stricter compliance requirements on chemical manufacturers
Technological disruption leading to new, more efficient production methods by competitors
Increased competition from both domestic and international chemical manufacturers
Potential for price wars in the pharmaceutical intermediate market
High debt-to-equity ratio (4.31) indicating potential liquidity issues
Low current ratio (0.59) suggesting challenges in meeting short-term obligations
moderate - The company's performance is linked to the overall health of the pharmaceutical sector, which is sensitive to GDP growth and consumer spending.
Rising interest rates could increase financing costs for the company, impacting its ability to invest in growth and potentially leading to lower valuation multiples.
minimal - The company does not heavily rely on credit for its operations, although high debt levels could pose risks if market conditions deteriorate.
value - Investors may be attracted to the stock due to its low price-to-sales ratio (1.4x) despite recent performance struggles.
high - The stock has exhibited significant volatility, with a 1-year return of -31.1%.